Trial Profile

Compassionate use program of STRO-002 in infants and children with relapsed/refractory CBF2AT3-GLIS2 acute myeloid leukemia

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 14 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Luveltamab tazevibulin (Primary) ; Cytarabine; Dasatinib; Decitabine; Fludarabine; Methotrexate
Indications Acute myeloid leukaemia
Focus Adverse reactions; Expanded access; Therapeutic Use

Most Recent Events

11 Dec 2023 Results published in the Media Release
11 Dec 2023 According to a Sutro Biopharma media release, data from this trial were in a poster presentation at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) in San Diego, CA.
13 Nov 2023 According to a Sutro Biopharma media release, updated data from this study to be presented in a poster at ASH 2023

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com